226 Studies Now Enrolling
Menu
Search
Medical Condition
- Show all (662)
- Autoimmune Disorders (1)
- (-) Blood Disorders (4)
- Cancer
(564)
- Bladder Cancer (13)
- Brain Cancer (12)
- Breast Cancer (60)
- Gastrointestinal (10)
- Gynecologic Cancer (30)
- Head and Neck Cancer (4)
- Kidney Cancer (7)
- Leukemia (64)
- (-) Liver Cancer (4)
- Lung Cancer (57)
- Lymphoma (24)
- Multiple Myeloma (24)
- Pancreatic Cancer (6)
- Prostate Cancer (25)
- Sarcoma (23)
- Skin Cancer (26)
- Solid Tumors (36)
- Thyroid Cancer (1)
- Uveal Melanoma (7)
- COVID-19 (Coronavirus) (1)
- Diabetes (2)
- Ear, Nose and Throat (1)
- Endocrine & Metabolic Disease (1)
- Gastrointestinal and Digestive Diseases (2)
- Healthy Volunteers (7)
- Heart Disease (2)
- Liver Disease (1)
- Neurological Disorders (22)
- Obesity (1)
- Obstetrics & Gynecology (6)
- Pediatrics (41)
- Psychiatric Disorders (1)
- Surgery (1)
- Transplant (3)
- Urology (1)
Displaying 1 - 8 of 8
Condition: Cancer / Liver Cancer
Investigator: Elizabeth Verna, MD
Status: Currently Recruiting
This study aims to use new technology involving molecular and imaging tests to help detect liver cancer early in patients. Participants enrolled will participate in it for approximately 5 years. The purpose of this study is to determine if an experimental drug, INT-787, is safe and effective in patients who are hospitalized…
Condition: Cancer / Liver Cancer
Investigator: Yvonne Saenger, MD
Status: Closed
The purpose of this study is to learn more about TPST-1120. The aims of the study are to find out if TPST-1120 can be given safely to people, to determine a safe dose of the study drug, if it is safe when given in combination with other anti-cancer drugs, what effects the drug may have, and to learn more about how the body…
Condition: Cancer / Liver Cancer
Investigator: Elizabeth Verna, MD
Status: Closed
Patients will be asked to participate in this research study because they have been diagnosed with hepatocellular carcinoma (HCC) which is a type of liver cancer. By doing this study, researchers hope to: Find out more about patients that have HCC including their age, race/ethnicity, and other medical conditions they may have…
Condition: Cancer / Liver Cancer
Investigator: Linda Wu, MD
Status: Closed
The purpose of this study is to compare the effects, good or bad, of tiragolumab plus atezolizumab plus bevacizumab versus placebo plus atezolizumab plus bevacizumab on patients with HCC. In this study, participants will be randomized you will get either tiragolumab plus atezolizumab plus bevacizumab or placebo plus atezolizumab plus bevacizumab. A placebo…
Condition: Blood Disorders
Investigator: Mark Heaney, MD, PhD
Status: Closed
This is a Phase 2 study for patients with myelofibrosis previously treated with one or more Janus Kinase(JAK) Inhibitor. A JAK inhibitor targets a certain pathway that may be causing cancer to grow, bystopping or inhibiting the cycle of development of the pathway. There is one JAK inhibitor that has beenapproved for the…
Condition: Blood Disorders
Investigator: Mark Heaney, MD, PhD
Status: Closed
The purpose of this study is to collect information on whether idasanutlin is effective in treating polycythemia vera (a slow-growing blood cancer in which your bone marrow makes too many red blood cells) and what effects, good or bad, idasanutlin has on you. Idasanutlin is an experimental drug, which means Health Authorities…
Condition: Blood Disorders / Amyloidosis
Investigator: Suzanne Lentzsch, MD
Status: Closed
This is a research study for subjects that have been previously treated for systemic light chain (AL)amyloidosis (a disease in which abnormal protein deposits can damage organs and tissues in your body) and nowrequire further treatment. The main purpose of this study is to evaluate the safety and determine the maximum tolerated dose of aninvestigational new…
Condition: Blood Disorders / Amyloidosis
Investigator: Suzanne Lentzsch, MD
Status: Closed
The purpose of this study is to test for any good and bad effects of the study drug called isatuximab. Isatuximab may or may not improve your AL amyloidosis, but it could also cause side effects. Isatuximab is not approved by the Food and Drug Administration (FDA). Isatuximab has been shown to have good effects in some patients with recurring multiple…